Compare Novo Nordisk A/S (NVO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Wells Fargo & Co — how do they compare? Novo Nordisk A/S trades at $45.93 (market cap $207.85B), while Wells Fargo & Co trades at $87.48 (market cap $264.66B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | WFC | |
|---|---|---|
Market Cap | $207.85B | $264.66B |
Sector | Health | Financials |
52-Week High | $63.98 | $96.40 |
52-Week Low | $35.29 | $73.42 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | 2.29% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
